Gedea Biotech is a Swedish, innovative women’s health company developing pHyph, the first antibiotic free treatment that both treats and prevents bacterial vaginosis. The vaginal tablet, pHyph treats bacterial vaginosis (BV) and prevents its recurrence by promoting a healthy vaginal microbiome, restoring the vaginal pH to its normal level of pH 4,0 – 4,5 and by breaking down the biofilm formed during BV under which the infectious bacteria begin to thrive. These mechanisms of action, together provide a beneficial environment for the healthy vaginal microbiome. The naturally occurring active ingredient GDA 001 in pHyph is well documented and is already approved as a food additive. A clinical cure rate for BV on par with antibiotics on the market, has been proven in two phase 2 trials, with a superior safety profile, lower recurrence rate and without causing secondary VVC infections as antibiotics do. In the pipeline, pHyph is further developed for treatment of vaginal candida infections. Gedea Biotech was founded in 2015 and is based in Lund, Sweden. Follow the us at Linkedin or visit our webpage.
